iBio, Inc. Stock 12‑Month Price Target Cut to $5.53, Implies 447% Upside

iBio, Inc. (IBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update SAN DIEGO, August 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic an

iBio (NASDAQ: IBIO) said it dosed the first participant in a Phase 1 trial of IBIO-600, its first obesity/cardiometabolic program to enter human testing. The randomized, double-blind, placebo-controlled single-ascending-dose study will assess safety, tolerability, PK/PD and body-composition effects in ~32 adults with overweight/obesity, with completion expected in 2H 2027.

NIO reported 4,165 battery swap stations and 5,376 charging stations in China, with 86.7% of energy delivered to non-NIO vehicles. The company aims to add 1,000 swap stations this year, with Geely Holding Group investing $2.4B in NIO Power. Onvo, a partner brand, has launched new models and expanded service centers. Retail investors on Stocktwits expressed bullish sentiment, with NIO shares down 31% YTD.

Equinor discovered gas at the Gullfaks field, which could sustain production. The well was drilled as part of a production well project. Equinor, Petoro, and OMV hold the license.

Dan Ives, a partner at Yorkville Ives, named Nvidia, Microsoft, Palantir, Apple, and CrowdStrike as his top tech stock picks for 2027. He highlighted a $4 trillion AI spending wave and set price targets: Nvidia ($300), Microsoft ($615), Palantir ($250), Apple ($400), and CrowdStrike ($335). The stocks have varied performance in 2026, with CrowdStrike up 126.50% and others showing modest gains.

Lululemon Athletica (LULU) has appointed Maggie Gauger as President and Chief Product Officer and Joseph Godsey as Chief Operating Officer. The changes are part of a broader leadership shake-up, with several senior executives departing. Analysts expect stable earnings of about US$1.4b and modestly lower profit margins around 12.4% over the next few years.